Arcutis Biotherapeutics Inc (NAS:ARQT)
$ 10.25 -0.59 (-5.44%) Market Cap: 1.20 Bil Enterprise Value: 1.15 Bil PE Ratio: 0 PB Ratio: 7.65 GF Score: 29/100

Arcutis Biotherapeutics Inc Provides Positive Atopic Dermatitis Program Updates Call Transcript

Sep 19, 2023 / 12:30PM GMT
Release Date Price: $6.53 (+1.56%)
Operator

Good day, and thank you for standing by. Welcome to the Arcutis Biotherapeutics Atopic Dermatitis Updates Call. (Operator Instructions) Please be advised that today's conference is being recorded. I would now like to hand the conference over to your speaker and then Eric, he's Head of Investor Relations, Eric McIntyre, you may begin.

Eric McIntyre
Arcutis Biotherapeutics, Inc. - Head of IR

Thank you, Tanya. Good morning, everyone, and thank you for joining our call this morning on the exciting data we've released recently across our atopic dermatitis program. The slides for today are available on the Investors section of our website. On the call this morning, we have Frank Watanabe, President and CEO; and Patrick Burnett, Chief Medical Officer; and we are also joined by Dr. Larry Eichenfield, Chief of Pediatric and Adolescent Dermatology at Rady's Children Hospital and Professor of Dermatology and Pediatrics at UC San Diego School of Medicine. I'd remind everyone quickly that we will be making forward-looking statements during this call and any of these

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot